Last reviewed · How we verify
HS-10390
At a glance
| Generic name | HS-10390 |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy (PHASE2)
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10390 CI brief — competitive landscape report
- HS-10390 updates RSS · CI watch RSS
- Hansoh BioMedical R&D Company portfolio CI